Paragon 28 Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 2/6

Paragon 28 şirketinin toplam hissedar öz sermayesi $139.4M ve toplam borcu $110.6M olup, bu da borç-öz sermaye oranını 79.3% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $302.0M ve $162.6M dir.

Anahtar bilgiler

79.3%

Borç/özkaynak oranı

US$110.62m

Borç

Faiz karşılama oranı	n/a
Nakit	US$39.15m
Eşitlik	US$139.43m
Toplam yükümlülükler	US$162.58m
Toplam varlıklar	US$302.01m

Son finansal sağlık güncellemeleri

We Think Paragon 28 (NYSE:FNA) Has A Fair Chunk Of Debt

Sep 18

Is Paragon 28 (NYSE:FNA) Using Too Much Debt?

Jun 07

Recent updates

Analysts Have Made A Financial Statement On Paragon 28, Inc.'s (NYSE:FNA) Third-Quarter Report

Nov 15

Paragon 28, Inc. (NYSE:FNA) Full-Year Results Just Came Out: Here's What Analysts Are Forecasting For This Year

Mar 03

After Leaping 29% Paragon 28, Inc. (NYSE:FNA) Shares Are Not Flying Under The Radar

Nov 28

Paragon 28 announces public offering of 6.5M shares

Jan 25

Paragon 28 guides Q4 and FY22 revenue outlook above consensus

Jan 10

Paragon 28 GAAP EPS of -$0.13 misses by $0.01, revenue of $46M beats by $3.52M

Nov 10

US$25.00: That's What Analysts Think Paragon 28, Inc. (NYSE:FNA) Is Worth After Its Latest Results

May 12

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: FNA 'nin kısa vadeli varlıkları ( $177.6M ) kısa vadeli yükümlülüklerini ( $50.7M ) aşıyor.

Uzun Vadeli Yükümlülükler: FNA şirketinin kısa vadeli varlıkları ( $177.6M ) uzun vadeli yükümlülüklerini ( $111.9M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: FNA 'nin net borç/öz sermaye oranı ( 51.3% ) yüksek olarak değerlendiriliyor.

Borcun Azaltılması: FNA şirketinin borç/öz sermaye oranının son 5 yılda azalıp azalmadığını belirlemek için yeterli veri yok.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: FNA şirketinin mevcut serbest nakit akışına göre bir yıldan az nakit akışı süresi bulunmaktadır.

Tahmini Nakit Akışı: FNA un, serbest nakit akışı her yıl % 38.6 oranında tarihi oranda azalmaya devam ederse bir yıldan az nakit akışı süresi vardır

Paragon 28 Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 2/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

We Think Paragon 28 (NYSE:FNA) Has A Fair Chunk Of Debt

Is Paragon 28 (NYSE:FNA) Using Too Much Debt?

Recent updates

Analysts Have Made A Financial Statement On Paragon 28, Inc.'s (NYSE:FNA) Third-Quarter Report

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Paragon 28, Inc. Raises Net Revenue Guidance for 2024

Bronstein, Gewirtz & Grossman, LLC Files Class Action Lawsuit Against Paragon 28, Inc

Johnson Fistel, LLP Announces Class Action Lawsuit Commencement on Behalf of Investors of Paragon 28, Inc

Paragon 28, Inc. to Report Q3, 2024 Results on Nov 12, 2024

Paragon 28, Inc. Launches the Phantom® Fibula Nail System for Less Invasive Fracture Repair

It's Down 28% But Paragon 28, Inc. (NYSE:FNA) Could Be Riskier Than It Looks

Rosen Law Firm Files Securities Class Action Lawsuit Against Paragon 28, Inc

We Think Paragon 28 (NYSE:FNA) Has A Fair Chunk Of Debt

Paragon 28, Inc. Launches the R3FLEX™? Stabilization System to Anatomically Repair Ankle Syndesmotic In Injury

Consensus EPS estimates fall by 13%

Paragon 28, Inc. Announces the Launch of SMART28 Case Management Portal

Paragon 28, Inc. Updates Revenue Guidance for the Full Year of 2024

Paragon 28, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Investors Give Paragon 28, Inc. (NYSE:FNA) Shares A 27% Hiding

Is Paragon 28 (NYSE:FNA) Using Too Much Debt?

Consensus EPS estimates fall by 32%

Price target decreased by 11% to US$16.00

Paragon 28, Inc. Reaffirms Revenue Guidance for the Year 2024

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Many Still Looking Away From Paragon 28, Inc. (NYSE:FNA)

Paragon 28, Inc., Annual General Meeting, May 17, 2024

Paragon 28, Inc. to Report Q1, 2024 Results on May 08, 2024

New minor risk - Share price stability

Paragon 28, Inc. Announces Chief Financial Officer Changes

Paragon 28, Inc. Adds to Suite of Novel Syndesmosis Repair Solutions with Launch of Grappler®? R3INFORCE™? Extraosseous Repair System

New major risk - Financial position

Co-Founder recently bought US$255k worth of stock

Consensus EPS estimates fall by 24%

Paragon 28, Inc. (NYSE:FNA) Full-Year Results Just Came Out: Here's What Analysts Are Forecasting For This Year

Full year 2023 earnings: EPS misses analyst expectations

Paragon 28, Inc. Provides Earnings Guidance for the Fiscal Year 2024

Paragon 28, Inc. to Report Q4, 2023 Results on Feb 29, 2024

Paragon 28, Inc. Launches Precision®? Mis Bunion System Offering Surgeons A Guided Minimally Invasive Surgical Solution for Treating Patients with Bunions

Paragon 28, Inc. Announces the Launch of the FJ2000™ Power Console and Burr System Designed Specifically for Foot and Ankle Procedures

New minor risk - Shareholder dilution

Paragon 28, Inc. Launches the Mister Tendon™ Harvester System – the First and Only Minimally Invasive Harvesting System for Fhl and Fdl Tendon Transfer Procedures

Paragon 28 Announces First Cases and Limited Market Release of the Bun-Yo-Matic™ – A Next Generation Clamp and Cut Guide System for Lapidus Bunion Procedures

Paragon 28, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year 2023

Paragon 28, Inc. Announce the Launch of the Grappler Knotless Anchor System and Bridgeline Tape

After Leaping 29% Paragon 28, Inc. (NYSE:FNA) Shares Are Not Flying Under The Radar

Paragon 28, Inc. Launches Beast Cortical Fibers

Third quarter 2023 earnings released: US$0.10 loss per share (vs US$0.13 loss in 3Q 2022)

Paragon 28, Inc. Reaffirms Revenue Guidance for the Year 2023

Price target decreased by 8.4% to US$25.00

Paragon 28, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Paragon 28®, Inc. Receives FDA Approval for Ide Feasibility Study of Its Smart Total Talus™ System for Use in Conjunction with the Apex 3D™ Total Ankle Replacement System

New minor risk - Financial position

Second quarter 2023 earnings released: US$0.13 loss per share (vs US$0.13 loss in 2Q 2022)

Paragon 28, Inc. to Report Q2, 2023 Results on Aug 02, 2023

Paragon 28 Launches Comprehensive Supramalleolar Osteotomy System

Jason Edie Step Down from the Position of Chief Technology Officer of Paragon 28, Inc

Paragon 28, Inc. Provides Revenue Guidance for the Year 2023

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus EPS estimates fall by 30%

Full year 2022 earnings: EPS misses analyst expectations

Paragon 28, Inc. to Report Q4, 2022 Results on Mar 02, 2023

Paragon 28, Inc. has completed a Follow-on Equity Offering in the amount of $110.5 million.

Paragon 28 announces public offering of 6.5M shares

Paragon 28, Inc. Announces Preliminary Unaudited Revenue Results for the Fourth Quarter and Full-Year Ended December 31, 2022

Paragon 28 guides Q4 and FY22 revenue outlook above consensus

Chief Commercial Officer exercised options and sold US$1.8m worth of stock

Paragon 28, Inc. Enters Settlement Agreement with Stryker Corp

Consensus forecasts updated

Insider recently sold US$1.1m worth of stock

High number of new directors

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Paragon 28, Inc. Revises Revenue Guidance for the Fourth Quarter and Full Year of 2022

Insider recently sold US$1.1m worth of stock

Paragon 28 GAAP EPS of -$0.13 misses by $0.01, revenue of $46M beats by $3.52M

Paragon 28, Inc. to Report Q3, 2022 Results on Nov 10, 2022

Chief Commercial Officer exercised options and sold US$59k worth of stock